Keene, Kimberly S.
King, Tari
Hwang, E. Shelley
Peng, Bo
McGuire, Kandace P.
Tapia, Coya
Zhang, Hong
Bae, Sejong
Nakhlis, Faina
Klauber-Demore, Nancy
Meszoely, Ingrid
Sabel, Michael S.
Willey, Shawna C.
Eterovic, Agda Karina
Hudis, Cliff
Wolff, Antonio C. http://orcid.org/0000-0003-3734-1063
De Los Santos, Jennifer
Thompson, Alastair
Mills, Gordon B.
Meric-Bernstam, Funda
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (UL1 TR000371, UL1 TR000371)
The Kleberg Foundation
Article History
Received: 23 January 2018
Revised: 9 July 2018
Accepted: 21 September 2018
First Online: 12 October 2018
Competing interests
: Gordon B. Mills serves as a Consultant and/or on the Scientific Advisory Board for the following companies Allostery, Inc., AstraZeneca, Catena Pharmaceuticals, Critical Outcome Technologies, ImmunoMet, Ionis, Medimmune, Nuevolution, Precision Medicine, Signalchem Lifesciences, Symphogen, Takeda/Millenium Pharmaceuticals, Tarveda. He has a financial interest in Catena Pharmaceuticals, ImmunoMet, PTV Ventures, Spindletop Ventures. He holds licensed technology in HRD assay to Myriad Genetics. He has sponsored research from AstraZeneca, Critical Outcome Technologies, Illumina, Ionis, Karus, Nanostring, Takeda/Millenium Pharmaceuticals. Funda Meric Bernstam has grant or research support from Novartis, AstraZeneca, Taiho, Genentech, Calithera, Debiopharma, Bayer, PUMA, Aileron, Jounce, CytoMx, eFFECTOR, Zymeworks, Curis, Pfizer. She is a paid consultant for Dialecta, Sumitomo Dainippon Pharma. She is on advisory committees/review panels/board membership for Inflection Biosciences, Clearlight Diagnostics, Pieris, Darwin Health, GRAIL. Hong Zhang is a consultant for Genentech/Roche. Nancy Klauber-Demore is the Chief Scientific Officer, Co-founder and shareholder for Enci Therapeutic INC. The remaining authors declare no competing interests.